- Trials with a EudraCT protocol (158)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (4)
158 result(s) found for: Cardiac Arrhythmia.
Displaying page 7 of 8.
EudraCT Number: 2006-006532-21 | Sponsor Protocol Number: 40054-22062 | Start Date*: 2008-10-27 | ||||||||||||||||
Sponsor Name:EORTC | ||||||||||||||||||
Full Title: Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer (PETACC-6) | ||||||||||||||||||
Medical condition: locally advanced rectal cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) GB (Completed) FR (Completed) DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-001659-37 | Sponsor Protocol Number: 26061 | Start Date*: 2007-06-25 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer | |||||||||||||
Full Title: Phase II Study of ZK 219477 in patients with recurrent glioblastoma | |||||||||||||
Medical condition: Phase II study of ZK 219477 in patients with recurrent glioblastoma. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) NL (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004636-25 | Sponsor Protocol Number: ACOTAS_G098 | Start Date*: 2021-06-17 | ||||||||||||||||
Sponsor Name:GERCOR | ||||||||||||||||||
Full Title: A phase II study to evaluate the rate of cardiovascular events during trifluridine/tipiracil +/-oxaliplatin treatment in colorectal/oesogastric adenocarcinoma patients that have experienced a pas... | ||||||||||||||||||
Medical condition: colorectal or oesogastric adenocarcinoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002816-30 | Sponsor Protocol Number: 01072021 | Start Date*: 2021-11-12 | |||||||||||
Sponsor Name:Department of Anaesthesiology, Aarhus University Hospital | |||||||||||||
Full Title: Individualised perioperative blood pressure and fluid therapy in oesophagectomy - Study protocol for a prospective randomised controlled trial | |||||||||||||
Medical condition: Oesophagectomy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001626-26 | Sponsor Protocol Number: OMT28-C0201 | Start Date*: 2019-01-23 | |||||||||||
Sponsor Name:OMEICOS Therapeutics GmbH | |||||||||||||
Full Title: A Placebo-controlled, double-blind, Randomized, dose finding phase II study on OMT-28 in MaIntenance of Sinus rhythm after Electrical cardioversion in patients with persistent Atrial Fibrillation (... | |||||||||||||
Medical condition: Persistent atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) BG (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002176-41 | Sponsor Protocol Number: 17HH4268 | Start Date*: 2019-09-03 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Imperial College of Science Technology and Medicine | ||||||||||||||||||||||||||||||||||||||
Full Title: PREvention of STroke in Intracerebral haemorrhaGE survivors with Atrial Fibrillation (PRESTIGE-AF) | ||||||||||||||||||||||||||||||||||||||
Medical condition: Ischaemic stroke prevention in patients with atrial fibrillation and previous intracerebral haemorrhage | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) ES (Ongoing) AT (Completed) FR (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003998-96 | Sponsor Protocol Number: AXAGIST | Start Date*: 2019-04-03 | |||||||||||
Sponsor Name:Centrum Onkologii – Instytut im. Marii Skłodowskiej - Curie | |||||||||||||
Full Title: A Phase II, single arm Study of avelumab In combination with Axitinib in Patients With unresectable/metastatic Gastrointestinal Stromal Tumor after failure of standard therapy - AXAGIST | |||||||||||||
Medical condition: GIST - unresectable/metastatic Gastrointestinal Stromal Tumor after failure of standard therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001400-29 | Sponsor Protocol Number: P150302J | Start Date*: 2018-03-16 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Treatment of severe refractory systemic lupus erythematosus by injection of allogeneic mesenchymal stem cells derived from the umbilical cord - MSC SLE | |||||||||||||
Medical condition: Treatment of Systemic Lupus Erythematosus refractory to standard treatments. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000728-41 | Sponsor Protocol Number: 06/02-29 jan'07 | Start Date*: 2008-09-12 | ||||||||||||||||
Sponsor Name:Maastro clinic | ||||||||||||||||||
Full Title: A phase I/II trial testing nelfinavir, an inhibitor of Akt signaling, in combination with preoperative chemoradiotherapy in patients with locally advanced rectal cancer | ||||||||||||||||||
Medical condition: A phase I/II trial testing nelfinavir, an inhibitor of Akt signaling, in combination with preoperative chemoradiotherapy with locally advanced rectal cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-005885-30 | Sponsor Protocol Number: B1321001 | Start Date*: 2010-01-12 | |||||||||||
Sponsor Name:Pfizer Ltd | |||||||||||||
Full Title: A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, SAFETY AND EFFICACY STUDY OF SITAXSENTAN SODIUM IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION | |||||||||||||
Medical condition: Pulmonary arterial hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) SK (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002093-12 | Sponsor Protocol Number: 1506-STBSG | Start Date*: 2017-07-04 | ||||||||||||||||
Sponsor Name:European Organisation for Research and Treatment of | ||||||||||||||||||
Full Title: A Phase II multicenter study comparing the efficacy of the oral angionenesis inhibitor nintedanib with the intravenous cytotoxis compound ifosfamide for treatment of patients with advanced metastat... | ||||||||||||||||||
Medical condition: Metastatic soft tissue sarcoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) PL (Completed) NL (Completed) ES (Completed) LT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-001739-28 | Sponsor Protocol Number: S63979 | Start Date*: 2020-05-20 | |||||||||||
Sponsor Name:UZLeuven | |||||||||||||
Full Title: A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19. | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002856-18 | Sponsor Protocol Number: RB12.079 | Start Date*: 2013-03-22 | ||||||||||||||||
Sponsor Name:CHRU de Brest | ||||||||||||||||||
Full Title: ALdosterone antagonist Chronic HEModialysis Interventional Survival Trial | ||||||||||||||||||
Medical condition: | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) BE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002138-22 | Sponsor Protocol Number: LDLL300.401 | Start Date*: 2017-09-15 | ||||||||||||||||
Sponsor Name:AOP Orphan Pharmaceuticals GmbH | ||||||||||||||||||
Full Title: Phase IV, multicenter, prospective, randomized, open-label, controlled study on Landiolol in patients with septic shock resident in ICUs | ||||||||||||||||||
Medical condition: Adult patients in ICU with septic shock who remain tachycardic (HR ≥95 bpm) and require vasopressor therapy to maintain a Mean arterial pressure (MAP) of ≥65 mmHg after a hemodynamic optimization p... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Completed) DE (Completed) CZ (Completed) SI (Completed) HU (Completed) LT (Completed) PL (Completed) EE (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-003005-10 | Sponsor Protocol Number: IGR2012/1883 | Start Date*: 2013-06-06 | |||||||||||||||||||||
Sponsor Name:Gustave Roussy | |||||||||||||||||||||||
Full Title: PHASE I-II STUDY OF VINBLASTINE IN COMBINATION WITH NILOTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH REFRACTORY OR RECURRENT LOW-GRADE GLIOMA | |||||||||||||||||||||||
Medical condition: Children, adolescents and young adults with refractory or recurrent low-grade gliomas, and children, adolescents and young adults with neurofibromatosis type 1 and previously untreated low-grade g... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Completed) FR (Ongoing) NL (Completed) ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016601-42 | Sponsor Protocol Number: F60002 IN 202 G0 | Start Date*: 2010-02-03 | |||||||||||
Sponsor Name:PIERRE FABRE MEDICAMENT | |||||||||||||
Full Title: A phase II multicentric study in adults with acute myelogenous leukaemia (AML) in first complete remission (CR1) using IV BuCy2 in a once daily Bu regimen targeting a narrow therapeutic window prio... | |||||||||||||
Medical condition: Acute myeloid leukaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000367-98 | Sponsor Protocol Number: TRA100773 | Start Date*: 2005-02-11 |
Sponsor Name:GlaxoSmithKline Research and Development Limited | ||
Full Title: A double-blind, randomised, placebo-controlled, parallel group study to investigate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of SB-497115-GR, a thrombopoietin recep... | ||
Medical condition: Immune thrombocytopenic purpura (ITP) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) SE (Completed) DE (Completed) EE (Completed) LV (Completed) IE (Completed) DK (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-000878-11 | Sponsor Protocol Number: OMO1.01.02 | Start Date*: 2017-06-08 | |||||||||||
Sponsor Name:OCTIMET Oncology NV | |||||||||||||
Full Title: A modular, multi-arm, multi-part, first time in patient study to evaluate the safety and tolerability of OMO-1, alone and in combination with anti-cancer treatments, in patients with locally advanc... | |||||||||||||
Medical condition: Locally advanced, unresectable or metastatic solid malignancies | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) NL (Prematurely Ended) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001032-12 | Sponsor Protocol Number: PANTHERA | Start Date*: 2008-10-28 | |||||||||||||||||||||
Sponsor Name:Universitätsklinikum Schleswig-Holstein | |||||||||||||||||||||||
Full Title: Phase 2 trial of pemetrexed (Alimta™) combined with paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer | |||||||||||||||||||||||
Medical condition: recurrent/advanced follicular, papillary or anaplastic thyroid cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Prohibited by CA) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003190-26 | Sponsor Protocol Number: RESTART13 | Start Date*: 2013-01-14 | |||||||||||
Sponsor Name:ACCORD (Academic and Clinical Central Office for Research & Development)
[...]
1. ACCORD (Academic and Clinical Central Office for Research & Development)
2. ACCORD (Academic and Clinical Central Office for Research & Development) |
|||||||||||||
Full Title: REstart or STop Antithrombotics Randomised Trial (RESTART) | |||||||||||||
Medical condition: Spontaneous Intracerebral Haemorrhage (ICH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
